false
0001676163
0001676163
2023-12-26
2023-12-26
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
Pursuant to Section 13 or 15(d) of The Securities
Exchange Act of 1934
Date of report (Date of earliest event reported):
December 26, 2023
SS INNOVATIONS INTERNATIONAL, INC.
(Exact name of registrant as specified in its charter)
Florida |
|
333-216054 |
|
47-3478854 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
1600 SE 15th Street, #512
Fort Lauderdale, Florida |
|
33316 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code: (954) 478-1410
(Former name or former
address, if changed since last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
Title of each Class |
|
Trading Symbol |
|
Name of each exchange on which registered |
None |
|
N/A |
|
N/A |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
As used in this Current Report on Form 8-K
(this “Report”), the terms “SSII,” “the Company,” “we,”
“us” and “our” refer to SS Innovations International, Inc. and its subsidiaries.
Item 8.01 Other Events.
On December 26, 2023, we issued a press
release announcing that SSII had reached a strategic partnership with Surgical Lab, Ltd., a Cairo-based medical device distributor,
to provide accessibility to the Company’s SSi Mantra Surgical Robotic System for the entire African continent.
A copy of the press release is included as Exhibit
99.1 to this Report.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: December 26, 2023 |
SS INNOVATIONS INTERNATIONAL, INC. |
|
|
|
|
By: |
/s/ Sudhir Srivastava |
|
|
Sudhir Srivastava, M.D.
Chairman and Chief Executive Officer |
2
Exhibit 99.1
SS Innovations Announces Strategic Partnership
with Surgical Lab for Distribution in Africa
Pan African Medical Device Distributor Surgical
Lab to place the SSi Mantra Surgical Robotic System in Healthcare Facilities across the African Continent
Surgical Lab has Begun Registration of SSi Mantra
in 27 African countries
Fort Lauderdale, FL., December 26, 2023 - News
Direct - SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII), a developer of
innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announces
it has entered a strategic, exclusive partnership with Surgical Lab, Ltd., a Cairo-based medical device distributor, to provide accessibility
to the SSi Mantra Surgical Robotic System for the entire African continent. This marks another significant milestone for SS Innovations.
Surgical Lab Managing Director, Ali Raei commented,
“At Surgical Lab, we believe in the power of collaborative action. We are thrilled to announce our strategic partnership with SS
Innovations, which furthers our commitment as the African Surgical Robotic enabler to enhance healthcare and improve the quality of life
by transforming the traditional surgical procedures into the revolutionary with integrated futuristic technologies.”
“This marks a significant step in our partnership
and a great milestone for our collective expansion plan. We have been discussing all the details with SS Innovations for over a year and
are committed to working together to build a more revolutionary healthcare industry for the future of Africa. My team and I are extremely
proud to share this initiative and thank SS Innovations for being a part of our mission. We are absolutely thrilled to share that Surgical
Lab has started working on the registration of SSi Mantra in 27 countries across Africa. We are looking forward to the new opportunities
this strategic partnership will present.”
Commenting on the strategic partnership, Dr. Ossama
Elraey Shibly, COO of the Advanced Technologies Group (ATG Holding) which is the parent company of Surgical Lab, said, “I believe
that SSi Mantra will serve a lot of patients and will lead the African countries to the next era of robotic surgery. In 2021, I came to
know about this innovative Indian MedTech company SS Innovations, developer of the SSi Mantra. I found it to be the only surgical system
worldwide that was created with a focus on cost-effectiveness. This will completely transform the landscape of robotic surgery by making
it accessible and available to underserved populations worldwide by decentralizing excellence. It has also undergone hundreds of validations
in India through its clinical use in over 40 different types of surgical procedures, in all multispecialty disciplines as well as heart
surgeries. It is great to see a company that wants to bring the power of robotics to the whole world.”
SS Innovations, President and COO, Dr. Vishwajyoti
Srivastava said, “It is very encouraging to become associated with companies from all corners of the globe whose vision falls in
line with your own. Our strategic partnership with Surgical Lab will allow us to extend the reach of our mission and vision across the
seas to the African continent. Keeping in mind that the goal of bringing affordable and advanced healthcare to all is very ambitious,
I am also fully aware that this cannot be done alone. This will require the participation of those who are aligned with a humanitarian
cause, aligned with a greater sense of service, that will ultimately result in gold standard healthcare for all countries, all communities,
and all walks of life. It is precisely strategic partnerships such as this, between SS Innovations and Surgical Lab, that will allow for
the delivery of advanced technologies like the SSi Mantra Surgical Robotic System, to the ‘forgotten world’ at large.”
The SSi Mantra Surgical
Robotic System is the first surgical system to be made in India, and one of the only systems in the world to be distinctly cost-effective
with broad-spectrum surgical applications including cardiac surgery. The System has been granted
regulatory approval in India, the United Arab Emirates and Guatemala. It is clinically validated in more than 40 different types of surgical
procedures, and more than 500 surgical procedures have been performed to date. SS Innovations expects to secure regulatory approvals in
the United States and Europe in 2024 and 2025.
About SS Innovations International, Inc.
SS Innovations
International, Inc. (OTC: SSII) is a developer of innovative surgical robotic technologies with a vision to make the benefits of robotic
surgery affordable and accessible to a larger part of the global population. SSII’s product range includes its proprietary “SSi
Mantra” surgical robotic system, and “SSi Mudra”, its wide range of surgical instruments capable of supporting a variety
of surgical procedures including robotic cardiac surgery. SSII’s business operations are headquartered in India and SSII has plans
to expand the presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions, globally. For more
information, visit SSII’s website at ssinnovations.com or LinkedIn for updates.
About
Surgical Lab, Ltd.
Surgical
Lab drives visibility, control and efficiency for patients, providers and healthcare professionals across the supply chain with proprietary
technology and solutions, an extensive product portfolio, advanced surgical products, as well as a robust portfolio of products and services
for our consumers to manage with developing a new era of healthcare all over Africa. For more information, visit Surgical Lab’s
website at http://surgical-lab.com.
About SSi Mantra
Supporting advanced, affordable, and accessible
robotic surgery, the SSi Mantra Surgical Robotic System provides the capabilities for multi-specialty usage including cardiothoracic,
head and neck, gynecology, urology, general surgery and more. With its modular arm configuration, 3D 4K vision open-console design and
superior ergonomics, the system engages with the surgeon and surgical teams to improve safety and efficiency during procedures.
The SSi Mantra system has received Indian Medical Device regulatory approval (CDSCO) and is clinically validated in India in more than
40 different types of surgical procedures. The company expects to seek regulatory approvals from the US Food and Drug Administration (FDA)
and CE Mark in Europe in 2024 and 2025.
Forward-Looking Statements
This press
release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities
Litigation Reform Act of 1995. The words “anticipate,” “assume,” “believe,” “estimate,”
“expect,” “will,” “intend,” “may,” “plan,” “project,” “should,”
“could,” “seek,” “designed,” “potential,” “forecast,” “target,”
“objective,” “goal,” or the negatives of such terms or other similar expressions to identify such forward-looking
statements. These statements relate to future events or SS Innovations International’s future financial performance and involve
known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements
to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking
statements.
For more information:
PCG Advisory
Stephanie Prince
sprince@pcgadvisory.com
(646) 863-6341
v3.23.4
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
AVRA Medical Robotics (PK) (USOTC:AVMR)
Historical Stock Chart
From May 2024 to Jun 2024
AVRA Medical Robotics (PK) (USOTC:AVMR)
Historical Stock Chart
From Jun 2023 to Jun 2024